Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04595851 · ClinicalTrials.gov registry record · NA
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT04595851: Clinical Trial NA study, sponsored by University of Michigan Rogel Cancer Center.
NCT04595851 is a NA study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04595851, a NA study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.
Primary Outcome
PDC is a common way to assess a patient's adherence to a medication regimen. PDC is the ratio of number of days the patient is supplied with OAA medication, from the time of OAA initiation until 6 months later, to the total number of days during that period. For OAAs, data from the electronic medical record (EMR) for dose changes will be aligned with the refill data to calculate a dose-adjusted PDC.
Interventions
- OTHER Patient Reported Outcome Measure (PROM)
- OTHER Comprehensive Medication Review (CMR)
- OTHER Communications between oncology and primary care pharmacists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2022-07-14 |
| Phase | NA |
Why NCT04595851 stopped before completion
NCT04595851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Patient Reported Outcome Measure (PROM) is the first listed.
NCT04595851 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04595851 about?
NCT04595851 is a clinical study titled "Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications". The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working...
What is the current status of trial NCT04595851?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2021-03-26. Estimated completion is 2022-07-14.
What interventions are being tested in trial NCT04595851?
The interventions under investigation include: Patient Reported Outcome Measure (PROM) (OTHER), Comprehensive Medication Review (CMR) (OTHER), Communications between oncology and primary care pharmacists (OTHER).
Who is sponsoring clinical trial NCT04595851?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04595851's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI